Ítem
Acceso Abierto

The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

Mostrar el registro sencillo de la publicación
dc.creatorBrown, Darron Rspa
dc.creatorKjaer, Susanne Kspa
dc.creatorSigurdsson, Kristjánspa
dc.creatorIversen, Ole-Erikspa
dc.creatorHernandez-Avila, Mauriciospa
dc.creatorWheeler, Cosette Mspa
dc.creatorPerez, Gonzalospa
dc.creatorKoutsky, Laura Aspa
dc.creatorTay, Eng Hseonspa
dc.creatorGarcia, Patricíaspa
dc.creatorAult, Kevin Aspa
dc.creatorGarland, Suzanne M.spa
dc.creatorLeodolter, Seppspa
dc.creatorOlsson, Sven-Ericspa
dc.creatorTang, Grace W Kspa
dc.creatorFerris, Daron G.spa
dc.creatorPaavonen, Jormaspa
dc.creatorSteben, Marcspa
dc.creatorBosch, F Xavierspa
dc.creatorDillner, Joakimspa
dc.creatorJoura, Elmar A.spa
dc.creatorKurman, Robert Jspa
dc.creatorMajewski, Slawomirspa
dc.creatorMuñoz, Nubiaspa
dc.creatorMyers, Evan Rspa
dc.creatorVilla, Luisa Lspa
dc.creatorTaddeo, Frank Jspa
dc.creatorRoberts, Christinespa
dc.creatorTadesse, Amhaspa
dc.creatorBryan, Janinespa
dc.creatorLupinacci, Lisa Cspa
dc.creatorGiacoletti, Katherine E Dspa
dc.creatorSings, Heather Lspa
dc.creatorJames, Margaretspa
dc.creatorHesley, Teresa Mspa
dc.creatorBarr, Eliavspa
dc.date.accessioned2020-05-25T23:56:15Z
dc.date.available2020-05-25T23:56:15Z
dc.date.created2009spa
dc.description.abstractBackground. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of-6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. Results. Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/ 33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. Conclusions. HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type. Trial registration. ClinicalTrials.gov identifiers: NCT00092521, NCT00092534, and NCT00092482. © 2009 by the Infectious Diseases Society of America.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1086/597307
dc.identifier.issn00221899
dc.identifier.issn15376613
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22373
dc.language.isoengspa
dc.relation.citationEndPage935
dc.relation.citationIssueNo. 7
dc.relation.citationStartPage926
dc.relation.citationTitleJournal of Infectious Diseases
dc.relation.citationVolumeVol. 199
dc.relation.ispartofJournal of Infectious Diseases, ISSN:00221899, 15376613, Vol.199, No.7 (2009); pp. 926-935spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-65549109389&doi=10.1086%2f597307&partnerID=40&md5=2f4ec2aa7fbcd569b37d56ce04b9d392spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordPlacebospa
dc.subject.keywordWart virus vaccinespa
dc.subject.keywordWart virus vaccinespa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordArticlespa
dc.subject.keywordCancer preventionspa
dc.subject.keywordClinical trialspa
dc.subject.keywordCondyloma acuminatumspa
dc.subject.keywordControlled clinical trialspa
dc.subject.keywordControlled studyspa
dc.subject.keywordDisease durationspa
dc.subject.keywordDouble blind procedurespa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordFemalespa
dc.subject.keywordHumanspa
dc.subject.keywordHuman papillomavirus type 11spa
dc.subject.keywordHuman papillomavirus type 16spa
dc.subject.keywordHuman papillomavirus type 18spa
dc.subject.keywordHuman papillomavirus type 31spa
dc.subject.keywordHuman papillomavirus type 45spa
dc.subject.keywordHuman papillomavirus type 6spa
dc.subject.keywordInfection preventionspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordPapanicolaou testspa
dc.subject.keywordPhase 3 clinical trialspa
dc.subject.keywordPriority journalspa
dc.subject.keywordRandomized controlled trialspa
dc.subject.keywordUterine cervix biopsyspa
dc.subject.keywordUterine cervix cancerspa
dc.subject.keywordUterine cervix carcinoma in situspa
dc.subject.keywordUterine cervix cytologyspa
dc.subject.keywordVaccinationspa
dc.subject.keywordAlphapapillomavirusspa
dc.subject.keywordClassificationspa
dc.subject.keywordGeneticsspa
dc.subject.keywordImmunologyspa
dc.subject.keywordUterine cervix tumorspa
dc.subject.keywordVirologyspa
dc.subject.keywordVirus infectionspa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordAlphapapillomavirusspa
dc.subject.keywordFemalespa
dc.subject.keywordHumansspa
dc.subject.keywordPapillomavirus infectionsspa
dc.subject.keywordPapillomavirus vaccinesspa
dc.subject.keywordUterine cervical neoplasmsspa
dc.subject.keywordYoung adultspa
dc.titleThe impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 yearsspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
199-7-926.pdf
Tamaño:
692.71 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos